Treace Medical Concepts Inc.
TMCI evidence brief
What we can confirm
- BioSniper Score:
- 7.7 / 10
- Market Cap:
- $292.0M
- Lead Asset:
- lapiplasty (Approved)
What it means
What to watch
Prepared research question
What matters most for TMCI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TMCI
Treace Medical Concepts Inc. (TMCI) is a publicly traded medical device company focused on surgical products for the foot and ankle market, with a history of net losses and a cash position of $12.6M as of 2026-06-30 [sec].
Key risk: Cash runway
BioSniper Score
Based on 4 of 6 signals
Market Cap
$292.0M
Cash Runway
—
Lead Asset
lapiplasty (Approved)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for Treace Medical Concepts Inc..
Treace Medical Concepts Inc. (TMCI) is a publicly traded medical device company focused on surgical products for the foot and ankle market, with a history of net losses and a cash position of $12.6M as of 2026-06-30 [sec].
- Cash & equivalents of $12.6M as of 2026-06-30 [sec].
- Total revenue of $45.4M for the trailing twelve months as of 2026-06-30 [sec].
- Net loss of -$15.9M for the trailing twelve months as of 2026-06-30 [sec].
- Shareholders' equity of $67.7M as of 2026-06-30 [sec].
- The company has incurred losses in the past and faces risks related to product adoption, competition, and supply chain [sec_mda · as of 2026-02-27].
What works
- The company has a product pipeline and is investing in R&D to maintain a competitive position in the foot and ankle surgery market [sec_mda · as of 2026-02-27].
- Shareholders' equity of $67.7M as of 2026-06-30 provides a capital base to support operations [sec].
What to weigh
- The company has incurred losses in the past and reported a net loss of -$15.9M for the trailing twelve months as of 2026-06-30 [sec].
- Cash & equivalents of $12.6M as of 2026-06-30 may be limited relative to ongoing operating expenses and potential future capital needs [sec].
- The company faces risks from single-source suppliers, product liability lawsuits, and the impact of tariffs and geopolitical tensions [sec_mda · as of 2026-08-07].
- If clinical studies do not continue to show positive outcomes, adoption of products may slow, harming business and financial condition [sec_mda · as of 2026-02-27].
From the filings
Quoted directly from source documents.
The company has incurred losses in the past and faces risks related to product adoption and competition.
“We have incurred losses in the past and”
SEC MD&A · February 27, 2026
The company faces risks from single-source suppliers and geopolitical tensions.
“the ability to obtain adequate supplies of materials and components for our products, including from single-source suppliers”
SEC MD&A · August 7, 2026
Catalyst timeline
- 2024-01-08 · Earnings Report - SEC 8-K filing — Quarterly earnings report filed with the SEC.
- 2024-02-27 · Earnings Report - SEC 8-K filing — Quarterly earnings report filed with the SEC.
- 2024-05-07 · Earnings Report - SEC 8-K filing — Quarterly earnings report filed with the SEC.
- 2024-08-06 · Earnings Report - SEC 8-K filing — Quarterly earnings report filed with the SEC.
- 2024-11-05 · Earnings Report - SEC 8-K filing — Quarterly earnings report filed with the SEC.
- 2025-01-13 · Earnings Report - SEC 8-K filing — Quarterly earnings report filed with the SEC.
- 2025-02-27 · Earnings Report - SEC 8-K filing — Quarterly earnings report filed with the SEC.
- 2025-05-08 · Earnings Report - SEC 8-K filing — Quarterly earnings report filed with the SEC.
Risks & what to watch (4)›
Key risks
- Cash runway — Cash & equivalents of $12.6M as of 2026-06-30 may be insufficient to cover ongoing losses and operating expenses [sec].
- Product adoption risk — If clinical studies do not show positive outcomes, adoption may slow, harming business [sec_mda · as of 2026-02-27].
- Supply chain disruption — Single-source suppliers and geopolitical tensions could disrupt material supply [sec_mda · as of 2026-08-07].
- Competitive pressure — Competitors may develop similar products and have greater resources for R&D and marketing [sec_mda · as of 2026-02-27].
What to watch
- Future earnings reports and financial filings for updates on revenue, net income, and cash position [sec_mda · as of 2026-08-07].
- Clinical study outcomes and product adoption trends in the foot and ankle surgery market [sec_mda · as of 2026-02-27].
- Developments in supply chain stability, particularly regarding single-source suppliers and tariff impacts [sec_mda · as of 2026-08-07].
Sources: Catalysts · SEC MD&A · Generated October 12, 2026 · How we verify sources →
Run Treace Medical Concepts Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Treace Medical Concepts Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 1.67 · 0% dilution
Lead: Approved
1 candidate
No upcoming catalysts tracked
12 buys · 0 sells (180d)
Pipeline
Financials
Short Interest
as of May 12, 2026- % of float
- 7.7%
- Days to cover
- 4.3
- Shares short
- 3,961,725
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TMCI short interestGovernance
Frequently asked questions
What is the AI investment thesis for Treace Medical Concepts Inc.?
Treace Medical Concepts Inc. (TMCI) is a publicly traded medical device company focused on surgical products for the foot and ankle market, with a history of net losses and a cash position of $12.6M as of 2026-06-30 [sec].
What is Treace Medical Concepts Inc.'s lead drug candidate?
Treace Medical Concepts Inc.'s most advanced tracked candidate is lapiplasty (Approved) for Bunions.
Who is the CEO of Treace Medical Concepts Inc.?
Mr. John T. Treace is the chief executive officer of Treace Medical Concepts Inc. (TMCI).
Where is Treace Medical Concepts Inc. headquartered?
Treace Medical Concepts Inc. (TMCI) is headquartered in Ponte Vedra, FL, United States.
What therapeutic areas does Treace Medical Concepts Inc. focus on?
Treace Medical Concepts Inc. develops therapies across Oncology, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.